Abstract
The earliest observations of the novel disorder, nephrogenic systemic fibrosis, were made in a renal transplantation unit of a medical center in Southern California in 1997 in patients with chronic renal disease undergoing renal dialysis. Many of these patients were recipients of kidney transplants, most of which had failed. The most apparent clinical manifestations were extensive and progressive cutaneous induration. Histopathological examination of skin biopsy specimens indicated that the disorder was distinct from scleroderma or morphea and resembled more closely scleromyxedema [1]. A detailed description of the first 15 cases was published in 2000 [2]. Nine of the fifteen patients had undergone a renal transplant and all had pre-existing chronic renal disease except for a single patient who had received dialysis for acute tubular necrosis. The manifestations consisted of extensive thickening, hardening and hyperpigmentation of the skin. Distinct papules and subcutaneous nodules were present in some of these patients as well as flexion contractures of the joints of the arms. These changes were observed predominantly on the lower extremities. Each patient initially received a dermatological diagnosis of fasciitis and myositis, scleroderma or calciphylaxis.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139:928–30.
Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1.
Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383–93.
Cowper SE. Nephrogenic Fibrosing Dermopathy (ICNSFR Website). 2001-2009. Available at http://www.pathmax.com/dermweb/. Accessed 27 Oct 2010.
Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease. J Am Acad Dermatol. 2003;48:55–60.
Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–72.
Streams BN, Liu V, Liégeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42–7.
Perazella MA, Ishibe S, Perazella MA, Reilly RF. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial. 2003;16:276–80.
Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903–6.
Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (Nephrogenic Fibrosing Dermopathy). Arthritis Rheum. 2004;50:2660–6.
Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated fibrosis (Nephrogenic Fibrosing Dermopathy). Muscle Nerve. 2004;30:569–77.
Mendoza FA, Artlett CM, Sandori N, et al. Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238–49.
Saenz A, Mandal R, Kradin R, et al. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch. 2006;449:389–91.
Kay J, Bazari H, Avery LL, et al. Case records of the Massachusetts General Hospital case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008;358:827–38.
Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008;73:1413–8.
Krous HF, Breisch E, Chadwick AE, et al. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing’s sarcoma, end-stage renal disease, and hemodialysis. Pediatr Dev Pathol. 2007;10:395–402.
Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54(suppl):S31–4.
Gibson SE, Farver CV, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130:209–12.
Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: a series in a non-western population. J Am Acad Dermatol. 2006;54:155–9.
Koreishi AF, Nazarian RM, Saenz AJ, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med. 2009;133:1943–8.
Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1745.
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–62.
Morcos SK. Nephrogenic systemic fibrosis following the administratin of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73–6.
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–57.
Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168–75.
Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807–16.
Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230–4.
Prince MR, Zhang HL, Roditi GH, et al. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298–308.
Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736–41.
Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141–4.
U.S. Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMark, Magnevist, ProHance, and MultiHance. June 8, 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053112.htm. Accessed 27 Oct 2010.
U.S. Food and Drug Administration. Information for healthcare professionals. Gadolinium-based contrast agents for magnetic resonance imaging marketed as Magnevist, MultiHance, Omniscan, OptiMark, ProHance). May 23, 2007. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142905.htm. Accessed 27 Oct 2010.
U.S. Food and Drug Administration. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed 27 Oct 2010.
Piera-Valázquez S, Sandorfi N, Jiménez SA. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. Skinmed. 2007;6:24–7.
Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358.
Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71–81.
Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes:collagen-secreting cells of the peripheral blood. J Immunol. 2004;36:598–606.
Leung N, Shaikh A, Cosio FG, et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant. 2010;10:558–62.
Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant. 2008;22:803–8.
Aires SB, Sotto MN, Nico MM. Nephrogenic fibrosing dermopathy: report of two cases. Acta Derm Venereol. 2007;87:521–4.
Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543–8.
Chandran S, Petersen J, Jacobs C, et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis. 2009;53:129–32.
Tran KT, Prather HB, Cockerell CJ, et al. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol. 2009;145:1170–4.
Kreuter A, Gambichler T, Weiner SM, et al. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol. 2008;144:1527–9.
Duffy KL, Green L, Harris R, et al. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol. 2008;59(2 Suppl 1):S39–40.
Wahba IM, White K, Meyer M, et al. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy–report of two cases and review of the literature. Nephrol Dial Transplant. 2007;22:631–6.
Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140:1322–4.
Mathur K, Morris S, Deighan C, et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher. 2008;23:144–50.
Kintossou R, D’Incan M, Chauveau D, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: role of gadolinium? Ann Dermatol Venereol. 2007;134:667–71.
Läuchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208:278–80.
Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531–6.
Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2008;23:3280–2.
Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis. 2009;53:133–7.
Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure–role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258–63.
Pieringer H, Schmekal B, Janko O, et al. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3094.
Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology. 2009;253:689–96.
Parsons AC, Yosipovitch G, Sheehan DJ, et al. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol. 2007;29:433–6.
Wilford C, Fine JD, Boyd AS, et al. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation. Am J Dermatopathol. 2010;32:71–5.
Neudecker BA, Stern R, Mark L, et al. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol. 2005;9:612–5.
Edward M, Fitzgerald L, Thind C, et al. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol. 2007;156:473–9.
Del Galdo F, Shaw MA, Jimenez SA. Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol. 2010;177:1638–46.
Honore B, Vorum H. The CREC family, a novel family of multiple EF-hand, low-affinity Ca2 + -binding proteins localised to the secretory pathway of mammalian cells. FEBS Lett. 2000;466:11–8.
Vorum H, Hager H, Christensen BM, et al. Human calumenin localizes to the secretory pathway and is secreted to the medium. Exp Cell Res. 1999;248:473–81.
Fukuda T, Oyamada H, Isshiki T, et al. Distribution and variable expression of secretory pathway protein reticulocalbin in normal human organs and non-neoplastic pathological conditions. J Histochem Cytochem. 2007;55:335–45.
Bassuk JA, Berg RA. Protein disulphide isomerase, a multifunctional endoplasmic reticulum protein. Matrix. 1989;9:244–58.
Kellokumpu S, Suokas M, Risteli L, Myllyla R. Protein disulfide isomerase and newly synthesized procollagen chains form higher-order structures in the lumen of the endoplasmic reticulum. J Biol Chem. 1997;272:2770–7.
Wilson R, Lees JF, Bulleid NJ. Protein disulfide isomerase acts as a molecular chaperone during the assembly of procollagen. J Biol Chem. 1998;273:9637–43.
Ko MK, Key EP. PDI-mediated ER retention and proteasomal degradation of procollagen I in corneal endothelial cells. Exp Cell Res. 2004;295:25–35.
Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis. 2010;69:2017–23.
Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T-cells. Proc Natl Acad Sci USA. 1997;94:6307–12.
Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998;160:419–25.
Schieren G, Gambichler T, Skrygan M, et al. Balance of profibrotic and antifibrotic signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis. 2010;55:1040–9.
High WA, Ayers J, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–6.
Thakral C, Abraham JL. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc. 2007;56:181–7.
Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging. 2007;2:199–205.
Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158:272–80.
Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol. 2009;36:1244–54.
Khurana A, Greene Jr JR, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with an analysis of clinical factors. J Am Acad Dermatol. 2008;59:218–24.
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710–2.
George SJ, Webb SM, Abraham JL, et al. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in nephrogenic systemic fibrosis. Br J Dermatol. 2010;163(5):1077–81.
Christensen KN, Lee CU, Hanley MM, et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011;64(1):91–6.
High WA, Ranville JF, Brown M, et al. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol. 2010;62:38–44.
Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 2008;5:45–52.
Bellin MF, Vasile M, Morel-Precetti S. Currently used nonspecific extracellular MR contrast media. Eur Radiol. 2003;13:2688–98.
Le Mignon MM, Chambon C, Warrington S, et al. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol. 1990;25:933–7.
Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29:709–15.
Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol. 2000;35:35–40.
Townsend RR, Cohen DL, Katholy R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis. 2000;36:1207–12.
Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502.
Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadoneate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34:443–55.
Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol. 1984;142:619–24.
Lansman JB. Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J Gen Physiol. 1990;95:679–96.
Biagi BA, Enyeart JJ. Gadolinium blocks low- and highthreshold calcium currents in pituitary cells. Am J Physiol. 1990;259:C515–20.
Itoh N, Kawakita M. Characterization of Gd3+ and Tb3+ binding sites on Ca2+, Mg2 + -adenosine triphosphatase of sarcoplasmic reticulum. J Biochem. (Tokyo). 1984;95:661–9.
Husztik E, Lazar G, Parducz A. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol. 1980;61:624–30.
Palasz A, Czekaj P. Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol. 2000;47:1107–14.
Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60:314–23.
Lorusso V, Pascolo L, Fernetti C, et al. Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Des. 2005;11:4079–98.
Tweedle MF. “Stability” of gadolinium chelates. Br J Radiol. 2007;80:581–2.
Schmitt-Willich H. Stability of gadolinium chelates. Br J Radiol. 2007;80:583–4.
Bussi S, Gouillet X, Morisetti A. Toxicological assessment of gadolinium release from contrast media. Exp Toxicol Pathol. 2007;58:323–30.
Sherry AD, Caravan P, Lenkinsi RE. Primer on gadolinium chemistry. J Magn Reson Imaging. 2009;30:1240–8.
Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30:1249–58.
Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging. Fundam Clin Pharmacol. 2006;20:563–76.
Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol. 2010;2:427–33.
Newton BB, Jimenez SA. Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging. 2009;30:1277–83.
Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 2009;60:1508–18.
Del Galdo F, Wermuth PJ, Addya S, et al. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis. 2010;69:2024–33.
Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;4:584–93.
Edward M, Quinn JA, Burden AD, et al. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology. 2010;256:735–43.
Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74–91.
Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433–9.
Bhagavathula N, Dame MK, DaSilva M, et al. Fibroblast reponse to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol. 2010;45(12):769–77.
DaSilva M, O’Brien Deming M, Fligiel SE, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733–9.
Vakil V, Sung JJ, Piecychna M, et al. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. J Magn Reson Imaging. 2009;30:1284–8.
Grant D, Johnsen H, Juelsrud A, et al. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156–69.
Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65–75.
Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging. 2008;27:955–62.
Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164–73.
Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis – a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol. 2009;61:537–52.
Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Long-term retention of gadolinium in the skin of reodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009;19:1417–24.
Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging. 2009;30:374–83.
Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology. 2009;253:390–8.
Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44:226–33.
Anders H, Schlondorff D. Murine models of renal disease: possibilities and problems in studies using mutant mice. Exp Nephrol. 2000;8:181–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wermuth, P.J., Jimenez, S.A. (2012). Nephrogenic Systemic Fibrosis. In: Varga, J., Denton, C., Wigley, F. (eds) Scleroderma. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-5774-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5774-0_13
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5773-3
Online ISBN: 978-1-4419-5774-0
eBook Packages: MedicineMedicine (R0)